ADAR1 Capital Management LLC Purchases New Shares in Replimune Group, Inc. $REPL

Key Points

• ADAR1 Capital Management acquired 655,784 Replimune shares worth approximately $7.26 million, representing about 0.78% of the company. Institutional investors collectively own 92.53% of Replimune.
• Replimune shares rose 7.4% to $15.80, near their 52-week high of $15.89, despite the company reporting a quarterly loss of $0.72 per share that missed analyst expectations.
• Analyst sentiment is mixed but leans positive, with a consensus “Moderate Buy” rating and an $11.86 price target; several firms recently upgraded the stock, while insiders have sold shares in recent months.

ADAR1 Capital Management LLC acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 655,784 shares of the company's stock, valued at approximately $7,260,000. ADAR1 Capital Management LLC owned about 0.78% of Replimune Group as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Replimune Group during the second quarter worth $99,171,000. Balyasny Asset Management L.P. grew its position in shares of Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company's stock worth $11,012,000 after buying an additional 2,195,448 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in shares of Replimune Group in the 4th quarter valued at about $17,568,000. Commodore Capital LP bought a new stake in shares of Replimune Group in the 4th quarter valued at about $13,851,000. Finally, EcoR1 Capital LLC bought a new stake in shares of Replimune Group in the 1st quarter valued at about $7,650,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Trading Up 7.4%

Shares of NASDAQ:REPL opened at $15.80 on Wednesday. The company's 50-day moving average price is $11.51 and its two-hundred day moving average price is $8.17. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $15.89. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The stock has a market capitalization of $1.48 billion, a PE ratio of -5.02 and a beta of 0.88.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). On average, equities analysts forecast that Replimune Group, Inc. will post -2.94 EPS for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the company's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sushil Patel sold 39,341 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the sale, the chief executive officer owned 708,151 shares of the company's stock, valued at $9,184,718.47. This trade represents a 5.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 91,124 shares of company stock valued at $1,149,244 in the last three months. Corporate insiders own 5.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings cut shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 11th. Piper Sandler upgraded shares of Replimune Group from a "hold" rating to a "strong-buy" rating in a report on Friday, July 31st. BMO Capital Markets raised shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price target on the stock in a research report on Tuesday, June 30th. Wall Street Zen raised shares of Replimune Group from a "strong sell" rating to a "sell" rating in a report on Saturday, May 23rd. Finally, Wedbush raised shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price target for the company in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $11.86.

Trending Headlines about Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: The stock’s recent rally has been linked to positive developments surrounding Replimune’s regulatory approval prospects, although the available report provides limited details on the underlying approval catalyst. Replimune's Approval Rally Carries a Legal Tailwind That Won't Let Go

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source